VasoPET is the only PET agent known to selectively target inflamed or vulnerable atheromatous plaque. With VasoPET, physicians identify dangerous coronary artery plaque – an unhealthy though typical accumulation of cell debris including cholesterol, calcium mineral and tissue within the walls.

The third important step in the cardiovascular disease market, FluoroPharma scientists determined that a significant opportunity existed to improve the true determination of the presence of atheromatous plaque, again offering true diagnostic sensitivity and specificity.

VasoPET is the first molecular imaging agent - diadenosine tetraphosphate is avidly taken up by inflammatory cells and rapidly dividing cells.